Literature DB >> 18403719

Conformational rearrangements and signaling cascades involved in ligand-biased mitogen-activated protein kinase signaling through the beta1-adrenergic receptor.

Ségolène Galandrin1, Geneviève Oligny-Longpré, Hélène Bonin, Koji Ogawa, Céline Galés, Michel Bouvier.   

Abstract

In recent years, several studies have demonstrated that different ligands can have distinct efficacy profiles toward various signaling pathways through a unique receptor. For example, beta1-adrenergic compounds that are inverse agonists toward the adenylyl cyclase (AC) can display agonist activity for the mitogen-activated protein kinase (MAPK) pathway. Such a phenomenon, often termed functional selectivity, has now been clearly established for many G protein-coupled receptors when considering distinct signaling output. However, the possibility that ligands could selectively engage distinct effectors to activate a single signaling output by promoting specific receptor conformations has not been extensively examined. Here, we took advantage of the fact that isoproterenol, bucindolol and propranolol (full, partial, and inverse agonists for the AC pathway, respectively) all activate MAPK through the beta1-adrenergic receptor (beta1AR) to probe such conformational-biased signaling. Although the three compounds stimulated MAPK in a src-dependent manner, isoproterenol acted through both Galpha(i)betagamma- and G protein-independent pathways, whereas bucindolol and propranolol promoted MAPK activation through the G protein-independent pathway only. The existence of such distinct signaling cascades linking beta1AR to MAPK activation was correlated with ligand-specific conformational rearrangements of receptor/G protein complexes measured by bioluminescence resonance energy transfer. Taken together, our data indicate that discrete local conformational changes can selectively promote the recruitment of distinct proximal signaling partners that can engage distinct signaling outputs and/or converge on the same signaling output.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18403719     DOI: 10.1124/mol.107.043893

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  44 in total

1.  Ligand-directed c-Jun N-terminal kinase activation disrupts opioid receptor signaling.

Authors:  Erica J Melief; Mayumi Miyatake; Michael R Bruchas; Charles Chavkin
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-03       Impact factor: 11.205

Review 2.  Probing heterotrimeric G protein activation: applications to biased ligands.

Authors:  Colette Denis; Aude Saulière; Segolene Galandrin; Jean-Michel Sénard; Céline Galés
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

3.  Engagement of β-arrestin by transactivated insulin-like growth factor receptor is needed for V2 vasopressin receptor-stimulated ERK1/2 activation.

Authors:  Geneviève Oligny-Longpré; Maithé Corbani; Joris Zhou; Mireille Hogue; Gilles Guillon; Michel Bouvier
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-09       Impact factor: 11.205

Review 4.  Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery.

Authors:  Terry Kenakin; Laurence J Miller
Journal:  Pharmacol Rev       Date:  2010-04-14       Impact factor: 25.468

Review 5.  Ensemble of G protein-coupled receptor active states.

Authors:  P S-H Park
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

Review 6.  Modulation of chemokine receptor activity through dimerization and crosstalk.

Authors:  C L Salanga; M O'Hayre; T Handel
Journal:  Cell Mol Life Sci       Date:  2009-04       Impact factor: 9.261

7.  Atypical pharmacologies at beta-adrenoceptors.

Authors:  R J Summers
Journal:  Br J Pharmacol       Date:  2008-07-21       Impact factor: 8.739

Review 8.  G protein-coupled receptor hetero-dimerization: contribution to pharmacology and function.

Authors:  Graeme Milligan
Journal:  Br J Pharmacol       Date:  2009-03-20       Impact factor: 8.739

Review 9.  The impact of GPCR structures on pharmacology and structure-based drug design.

Authors:  Miles Congreve; Fiona Marshall
Journal:  Br J Pharmacol       Date:  2009-11-13       Impact factor: 8.739

10.  Agonist-biased signaling via proteinase activated receptor-2: differential activation of calcium and mitogen-activated protein kinase pathways.

Authors:  Rithwik Ramachandran; Koichiro Mihara; Maneesh Mathur; Moulay Driss Rochdi; Michel Bouvier; Kathryn Defea; Morley D Hollenberg
Journal:  Mol Pharmacol       Date:  2009-07-15       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.